Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy
Purpose To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients. Methods A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate ef...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2017-03, Vol.79 (3), p.595-602 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 602 |
|---|---|
| container_issue | 3 |
| container_start_page | 595 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 79 |
| creator | Kasuga, Akiyoshi Hamamoto, Yasuo Takeuchi, Ayano Kawasaki, Kenta Suzuki, Takeshi Hirata, Kenro Sukawa, Yasutaka Takaishi, Hiromasa Kanai, Takanori |
| description | Purpose
To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients.
Methods
A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogeneity of first-line regimens. We evaluated the relation between OS and either progression-free survival (PFS) or PPS. We also examined whether any association might be affected by the year of completion of trial enrollment.
Results
For all 54 trials, PPS was strongly associated with OS (
r
= 0.844), whereas PFS was moderately associated with OS (
r
= 0.623). Average OS and PPS were significantly longer in recent trials than in older trials, (7.29 versus 6.15 months,
p
|
| doi_str_mv | 10.1007/s00280-017-3263-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881754386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1872575635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-49c2d7213b1d92af7105cf83bd9b6c3bfd4cfc76e405483d5bb4fdec9d507b163</originalsourceid><addsrcrecordid>eNqNkc2OFCEUhYnROD2jD-DGkLhxg_JbVLszEx1NJtGFritAXaaZVEEJVE_6hXxOGXv8TUxccQnfOQc4CD1h9AWjVL8slPKeEso0EbwTRNxDGyYFJ7SX4j7aUCElUZrKE3RayjWlVDIhHqIT3nPRte0Gff2YSqhhDzjDZGpIsezCgi3UG4CIy2oLfFkhVux2MKe6g2yWAzZxxGnf5mlqTN6HvZlwiHgx0WVoPg67NkJ-hWeohphopkMJBSePl1TqktNVhlJa3i-9Txn7kEslU4jwR-Aj9MCbqcDju_UMfX775tP5O3L54eL9-etL4qRmlcit46PmTFg2brnxmlHlfC_suLWdE9aP0nmnO5BUyV6MylrpR3DbUVFtWSfO0POjb7tge3apwxyKg2kyEdJaBtb3TCsp-v9BNVdadUI19Nlf6HVac_uS75TqeiYpaxQ7Ui6nUjL4YclhNvkwMDrc9j0c-x5a38Nt34Nomqd3zqudYfyp-FFwA_gRKO0oXkH-Lfqfrt8AxNu6iw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1875681401</pqid></control><display><type>article</type><title>Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Kasuga, Akiyoshi ; Hamamoto, Yasuo ; Takeuchi, Ayano ; Kawasaki, Kenta ; Suzuki, Takeshi ; Hirata, Kenro ; Sukawa, Yasutaka ; Takaishi, Hiromasa ; Kanai, Takanori</creator><creatorcontrib>Kasuga, Akiyoshi ; Hamamoto, Yasuo ; Takeuchi, Ayano ; Kawasaki, Kenta ; Suzuki, Takeshi ; Hirata, Kenro ; Sukawa, Yasutaka ; Takaishi, Hiromasa ; Kanai, Takanori</creatorcontrib><description>Purpose
To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients.
Methods
A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogeneity of first-line regimens. We evaluated the relation between OS and either progression-free survival (PFS) or PPS. We also examined whether any association might be affected by the year of completion of trial enrollment.
Results
For all 54 trials, PPS was strongly associated with OS (
r
= 0.844), whereas PFS was moderately associated with OS (
r
= 0.623). Average OS and PPS were significantly longer in recent trials than in older trials, (7.29 versus 6.15 months,
p
< 0.001) and (3.64 versus 2.86 months,
p
< 0.001), respectively. The correlation between OS and PPS in recent trials was much stronger than that in older trials (
r
= 0.846 versus 0.729). The relation between OS and PFS in recent and older trials did not differ (
r
= 0.595 versus 0.563). The percentage of patients with post-trial treatment was significantly higher in recent trials than in older trials (52.7 versus 39.7%,
p
< 0.001). The rate of post-trial anticancer therapy was significantly associated with OS (
r
= 0.910).
Conclusions
We found an increase in median PPS in accordance with an increase in median OS in recent trials compared with older trials and that rate of post-trial anticancer therapy was strongly associated with median OS. It is important that researchers be aware of these findings in designing clinical trials of first-line chemotherapy for pancreatic cancer patients.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-017-3263-3</identifier><identifier>PMID: 28236000</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer Research ; Disease-Free Survival ; Humans ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pharmacology/Toxicology ; Randomized Controlled Trials as Topic ; Survival Analysis</subject><ispartof>Cancer chemotherapy and pharmacology, 2017-03, Vol.79 (3), p.595-602</ispartof><rights>Springer-Verlag Berlin Heidelberg 2017</rights><rights>Cancer Chemotherapy and Pharmacology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-49c2d7213b1d92af7105cf83bd9b6c3bfd4cfc76e405483d5bb4fdec9d507b163</citedby><cites>FETCH-LOGICAL-c471t-49c2d7213b1d92af7105cf83bd9b6c3bfd4cfc76e405483d5bb4fdec9d507b163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-017-3263-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-017-3263-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28236000$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kasuga, Akiyoshi</creatorcontrib><creatorcontrib>Hamamoto, Yasuo</creatorcontrib><creatorcontrib>Takeuchi, Ayano</creatorcontrib><creatorcontrib>Kawasaki, Kenta</creatorcontrib><creatorcontrib>Suzuki, Takeshi</creatorcontrib><creatorcontrib>Hirata, Kenro</creatorcontrib><creatorcontrib>Sukawa, Yasutaka</creatorcontrib><creatorcontrib>Takaishi, Hiromasa</creatorcontrib><creatorcontrib>Kanai, Takanori</creatorcontrib><title>Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients.
Methods
A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogeneity of first-line regimens. We evaluated the relation between OS and either progression-free survival (PFS) or PPS. We also examined whether any association might be affected by the year of completion of trial enrollment.
Results
For all 54 trials, PPS was strongly associated with OS (
r
= 0.844), whereas PFS was moderately associated with OS (
r
= 0.623). Average OS and PPS were significantly longer in recent trials than in older trials, (7.29 versus 6.15 months,
p
< 0.001) and (3.64 versus 2.86 months,
p
< 0.001), respectively. The correlation between OS and PPS in recent trials was much stronger than that in older trials (
r
= 0.846 versus 0.729). The relation between OS and PFS in recent and older trials did not differ (
r
= 0.595 versus 0.563). The percentage of patients with post-trial treatment was significantly higher in recent trials than in older trials (52.7 versus 39.7%,
p
< 0.001). The rate of post-trial anticancer therapy was significantly associated with OS (
r
= 0.910).
Conclusions
We found an increase in median PPS in accordance with an increase in median OS in recent trials compared with older trials and that rate of post-trial anticancer therapy was strongly associated with median OS. It is important that researchers be aware of these findings in designing clinical trials of first-line chemotherapy for pancreatic cancer patients.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer Research</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pharmacology/Toxicology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Survival Analysis</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkc2OFCEUhYnROD2jD-DGkLhxg_JbVLszEx1NJtGFritAXaaZVEEJVE_6hXxOGXv8TUxccQnfOQc4CD1h9AWjVL8slPKeEso0EbwTRNxDGyYFJ7SX4j7aUCElUZrKE3RayjWlVDIhHqIT3nPRte0Gff2YSqhhDzjDZGpIsezCgi3UG4CIy2oLfFkhVux2MKe6g2yWAzZxxGnf5mlqTN6HvZlwiHgx0WVoPg67NkJ-hWeohphopkMJBSePl1TqktNVhlJa3i-9Txn7kEslU4jwR-Aj9MCbqcDju_UMfX775tP5O3L54eL9-etL4qRmlcit46PmTFg2brnxmlHlfC_suLWdE9aP0nmnO5BUyV6MylrpR3DbUVFtWSfO0POjb7tge3apwxyKg2kyEdJaBtb3TCsp-v9BNVdadUI19Nlf6HVac_uS75TqeiYpaxQ7Ui6nUjL4YclhNvkwMDrc9j0c-x5a38Nt34Nomqd3zqudYfyp-FFwA_gRKO0oXkH-Lfqfrt8AxNu6iw</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Kasuga, Akiyoshi</creator><creator>Hamamoto, Yasuo</creator><creator>Takeuchi, Ayano</creator><creator>Kawasaki, Kenta</creator><creator>Suzuki, Takeshi</creator><creator>Hirata, Kenro</creator><creator>Sukawa, Yasutaka</creator><creator>Takaishi, Hiromasa</creator><creator>Kanai, Takanori</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20170301</creationdate><title>Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy</title><author>Kasuga, Akiyoshi ; Hamamoto, Yasuo ; Takeuchi, Ayano ; Kawasaki, Kenta ; Suzuki, Takeshi ; Hirata, Kenro ; Sukawa, Yasutaka ; Takaishi, Hiromasa ; Kanai, Takanori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-49c2d7213b1d92af7105cf83bd9b6c3bfd4cfc76e405483d5bb4fdec9d507b163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer Research</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pharmacology/Toxicology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kasuga, Akiyoshi</creatorcontrib><creatorcontrib>Hamamoto, Yasuo</creatorcontrib><creatorcontrib>Takeuchi, Ayano</creatorcontrib><creatorcontrib>Kawasaki, Kenta</creatorcontrib><creatorcontrib>Suzuki, Takeshi</creatorcontrib><creatorcontrib>Hirata, Kenro</creatorcontrib><creatorcontrib>Sukawa, Yasutaka</creatorcontrib><creatorcontrib>Takaishi, Hiromasa</creatorcontrib><creatorcontrib>Kanai, Takanori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kasuga, Akiyoshi</au><au>Hamamoto, Yasuo</au><au>Takeuchi, Ayano</au><au>Kawasaki, Kenta</au><au>Suzuki, Takeshi</au><au>Hirata, Kenro</au><au>Sukawa, Yasutaka</au><au>Takaishi, Hiromasa</au><au>Kanai, Takanori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>79</volume><issue>3</issue><spage>595</spage><epage>602</epage><pages>595-602</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Purpose
To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients.
Methods
A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogeneity of first-line regimens. We evaluated the relation between OS and either progression-free survival (PFS) or PPS. We also examined whether any association might be affected by the year of completion of trial enrollment.
Results
For all 54 trials, PPS was strongly associated with OS (
r
= 0.844), whereas PFS was moderately associated with OS (
r
= 0.623). Average OS and PPS were significantly longer in recent trials than in older trials, (7.29 versus 6.15 months,
p
< 0.001) and (3.64 versus 2.86 months,
p
< 0.001), respectively. The correlation between OS and PPS in recent trials was much stronger than that in older trials (
r
= 0.846 versus 0.729). The relation between OS and PFS in recent and older trials did not differ (
r
= 0.595 versus 0.563). The percentage of patients with post-trial treatment was significantly higher in recent trials than in older trials (52.7 versus 39.7%,
p
< 0.001). The rate of post-trial anticancer therapy was significantly associated with OS (
r
= 0.910).
Conclusions
We found an increase in median PPS in accordance with an increase in median OS in recent trials compared with older trials and that rate of post-trial anticancer therapy was strongly associated with median OS. It is important that researchers be aware of these findings in designing clinical trials of first-line chemotherapy for pancreatic cancer patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28236000</pmid><doi>10.1007/s00280-017-3263-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2017-03, Vol.79 (3), p.595-602 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1881754386 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Disease-Free Survival Humans Medicine Medicine & Public Health Oncology Original Article Pancreatic cancer Pancreatic Neoplasms - drug therapy Pharmacology/Toxicology Randomized Controlled Trials as Topic Survival Analysis |
| title | Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A18%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Positive%20relationship%20between%20subsequent%20chemotherapy%20and%20overall%20survival%20in%20pancreatic%20cancer:%20meta-analysis%20of%20postprogression%20survival%20for%20first-line%20chemotherapy&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Kasuga,%20Akiyoshi&rft.date=2017-03-01&rft.volume=79&rft.issue=3&rft.spage=595&rft.epage=602&rft.pages=595-602&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-017-3263-3&rft_dat=%3Cproquest_cross%3E1872575635%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1875681401&rft_id=info:pmid/28236000&rfr_iscdi=true |